Search

MAX phases are ternary carbide and/or nitride with a great potential in various application. This study concerned two MAX phase compounds, namely Ti3SiC2 and Ti2AlC, which are on the most studied among all known MAX phases. The first part dealt with materials elaboration which includes both synthesis and sintering stages. The objective was to obtain a variety of materials with different microstructural features, i.e. phase composition and grain size. For this purpose, both commercial and SHS-derived powders were densified with two pressure-assisted sintering technique, i.e. SPS and HP. The second part of work was devoted to deeper understanding of the influence of phase composition and grain size to thermomechanical behavior of MAX phases. More information was provided when two experimental techniques, four-point bending and AE monitoring, were coupled together with post-mortem SEM observations. The developed experimental approach based on comparison of mechanical responses of Ti3SiC2 (MAX phase and secondary phases) and Ti2AlC (containing only MAX phases) compounds, is implemented to investigate the induced deformation and damage mechanisms. It was shown that higher quantity of MAX phases in the material improves flexural strength with corresponding more pronounce nonlinear behavior and high dissipated energy. When MAX phase grains are coarser the mechanical strength lowers but the nonlinear part becomes more significative, which results in higher values of dissipated energy. It was also shown that the secondary phases and the grain size impact the way in which the damage is accumulated within the sample. AE data provided more information on possible damage mechanisms and their chronology leading to hysteretic behavior of MAX phases. The last part has shown that the BPTT for Ti3SiC2 is ≈1200˚C and the grain size of MAX phases lowers this BPTT.; Les phases MAX sont des carbures et / ou des nitrures ternaires avec un fort potentiel dans des applications diverses. Cette étude a porté sur deux phases MAX, Ti3SiC2 et Ti2AlC qui sont les plus connues dans ce groupe de matériaux. La première partie de ces travaux était dédiée à l’élaboration des poudres et des matériaux frittés. L’objectif était d’obtenir une variété de matériaux présentant différentes caractéristiques microstructurales, en termes de composition chimique et de taille de grains. Ainsi, des poudres commerciales et synthétisées par SHS ont été densifiées à l'aide de deux techniques de frittage sous charge, i.e. SPS et HP. La deuxième partie du travail a été consacrée à une meilleure compréhension de l’influence de la composition chimique et de la taille des grains sur le comportement thermomécanique des phases MAX. Des informations supplémentaires ont été fournies en couplant deux techniques expérimentales, la flexion quatre points et l’émission acoustique, et en les associant à des observations SEM post-mortems. L’approche expérimentale développée, basée sur la comparaison des réponses mécaniques des matériaux Ti3SiC2 (contenant la phase MAX et des phases secondaires) et de Ti2AlC (phases MAX uniquement), a permis d’approfondir la compréhension des mécanismes de déformation et d’endommagement induits. Il était également montré que les phases sécondaires et la taille de grains influence la manière dont les différents endommagements sont accumulées dans le matériaux. Les résultats d’EA sont fourni les informations supplémentaires sur les type d’endommagements rencontrées et leur chronologie qui résultent avec le comportement nonlinéaire de phases MAX. La dérnière partie de cette thèse a montré que le température de transition fragile-plastique est autour de 1200˚C et que la taille de grains l’abaisse.

International audience

International audience

International audience

Rates of tobacco smoking are high in people with schizophrenia with greater difficulty of quitting smoking compared to the general population, which also relate to the increased cardiovascular and cancer risks in this co-occurring disorder. Therefore, effective smoking cessation pharmacotherapies addressing tobacco co-morbidity are imperative. In this review, the authors performed an extensive systematic electronic literature review examining the efficacy and safety of first-line pharmacotherapies for smoking cessation, including varenicline, sustained-release bupropion, and nicotine replacement therapies (NRT) using continuous abstinence rates over 10-12-week periods in smokers with schizophrenia. Twelve trials reporting smoking cessation outcomes using interventions in schizophrenia were included and risk ratio (RR) was used. Our findings support the efficacy and safety of first-line pharmacotherapies for the treatment of tobacco use disorder in smokers with schizophrenia. Further research on the long-term effectiveness and safety of these agents in community samples is warranted. Smoking cessation pharmacotherapies may warrant the consideration of the emerging use of electronic nicotine delivery systems while neuromodulation techniques also offer promise.

Rates of tobacco smoking are high in people with schizophrenia with greater difficulty of quitting smoking compared to the general population, which also relate to the increased cardiovascular and cancer risks in this co-occurring disorder. Therefore, effective smoking cessation pharmacotherapies addressing tobacco co-morbidity are imperative. In this review, the authors performed an extensive systematic electronic literature review examining the efficacy and safety of first-line pharmacotherapies for smoking cessation, including varenicline, sustained-release bupropion, and nicotine replacement therapies (NRT) using continuous abstinence rates over 10-12-week periods in smokers with schizophrenia. Twelve trials reporting smoking cessation outcomes using interventions in schizophrenia were included and risk ratio (RR) was used. Our findings support the efficacy and safety of first-line pharmacotherapies for the treatment of tobacco use disorder in smokers with schizophrenia. Further research on the long-term effectiveness and safety of these agents in community samples is warranted. Smoking cessation pharmacotherapies may warrant the consideration of the emerging use of electronic nicotine delivery systems while neuromodulation techniques also offer promise.